References
  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [published correction appears in CA Cancer J Clin. 2020 Jul;70(4):313]. CA Cancer J Clin . 2018;68(6):394-424. doi:10.3322/caac.21492
  2. Lin S, Gao K, Gu S, et al. Worldwide trends in cervical cancer incidence and mortality, with predictions for the next 15 years. Cancer . 2021;127(21):4030-4039. doi:10.1002/cncr.33795
  3. https://ictv.global/report/chapter/papillomaviridae/papillomaviridae (Accessed 23 June 2023).
  4. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet . 2007;370(9590):890-907. doi:10.1016/S0140-6736(07)61416-0
  5. Bosch FX, de Sanjosé S. The epidemiology of human papillomavirus infection and cervical cancer. Dis Markers . 2007;23(4):213-227. doi:10.1155/2007/914823
  6. Schiffman M, Wentzensen N, Wacholder S, Kinney W, Gage JC, Castle PE. Human papillomavirus testing in the prevention of cervical cancer. J Natl Cancer Inst . 2011;103(5):368-383. doi:10.1093/jnci/djq562
  7. Ronco G, Dillner J, Elfström KM, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials [published correction appears in Lancet. 2015 Oct 10;386(10002):1446]. Lancet . 2014;383(9916):524-532. doi:10.1016/S0140-6736(13)62218-7
  8. Bhatla N, Singhal S. Primary HPV screening for cervical cancer. Best Pract Res Clin Obstet Gynaecol . 2020;65:98-108. doi:10.1016/j.bpobgyn.2020.02.008
  9. Cuzick J, Clavel C, Petry KU, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer . 2006;119(5):1095-1101. doi:10.1002/ijc.21955
  10. Schiffman M, Doorbar J, Wentzensen N, et al. Carcinogenic human papillomavirus infection. Nat Rev Dis Primers . 2016;2:16086. Published 2016 Dec 1. doi:10.1038/nrdp.2016.86
  11. Castle PE, Stoler MH, Wright TC Jr, Sharma A, Wright TL, Behrens CM. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. Lancet Oncol . 2011;12(9):880-890. doi:10.1016/S1470-2045(11)70188-7
  12. Arbyn M, Ronco G, Anttila A, et al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer [published correction appears in Vaccine. 2013 Dec 16;31(52):6266]. Vaccine . 2012;30 Suppl 5:F88-F99. doi:10.1016/j.vaccine.2012.06.095
  13. Maver PJ, Poljak M. Primary HPV-based cervical cancer screening in Europe: implementation status, challenges, and future plans. Clin Microbiol Infect . 2020;26(5):579-583. doi:10.1016/j.cmi.2019.09.006
  14. Perkins RB, Guido RS, Castle PE, et al. 2019 ASCCP Risk-Based Management Consensus Guidelines: Updates Through 2023. J Low Genit Tract Dis . 2024;28(1):3-6. doi:10.1097/LGT.0000000000000788
  15. Perkins RB, Guido RS, Castle PE, et al. 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors [published correction appears in J Low Genit Tract Dis. 2020 Oct;24(4):427]. J Low Genit Tract Dis . 2020;24(2):102-131. doi:10.1097/LGT.0000000000000525
  16. Perkins RB, Wentzensen N, Guido RS, Schiffman M. Cervical Cancer Screening: A Review. JAMA . 2023;330(6):547-558. doi:10.1001/jama.2023.13174
  17. Giorgi Rossi P, Carozzi F, Ronco G, et al. p16/ki67 and E6/E7 mRNA Accuracy and Prognostic Value in Triaging HPV DNA-Positive Women [published correction appears in J Natl Cancer Inst. 2021 Jul 17;:]. J Natl Cancer Inst . 2021;113(3):292-300. doi:10.1093/jnci/djaa105
  18. Premarket Approval (PMA). Available online: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P190 024 (Accessed 12 May 2023)
  19. Wentzensen N, Schiffman M, Palmer T, Arbyn M. Triage of HPV positive women in cervical cancer screening. J Clin Virol . 2016;76 Suppl 1(Suppl 1):S49-S55. doi:10.1016/j.jcv.2015.11.015
  20. Zhang R, Ge X, You K, et al. p16/Ki67 dual staining improves the detection specificity of high-grade cervical lesions. J Obstet Gynaecol Res . 2018;44(11):2077-2084. doi:10.1111/jog.13760
  21. Wright TC Jr, Behrens CM, Ranger-Moore J, et al. Triaging HPV-positive women with p16/Ki-67 dual-stained cytology: Results from a sub-study nested into the ATHENA trial. Gynecol Oncol . 2017;144(1):51-56. doi:10.1016/j.ygyno.2016.10.031
  22. Luttmer R, Dijkstra MG, Snijders PJ, et al. p16/Ki-67 dual-stained cytology for detecting cervical (pre)cancer in a HPV-positive gynecologic outpatient population. Mod Pathol . 2016;29(8):870-878. doi:10.1038/modpathol.2016.80
  23. Jach R, Mazurec M, Trzeszcz M, Zimmer M, Kedzia W, Wolski H. Cervical cancer screening in Poland in current SARS-CoV-2 pandemic: Interim guidelines of the Polish Society of Gynecologists and Obstetricians and the Polish Society of Colposcopy and Cervical Pathophysiology - a summary January 2021. Ginekol Pol . 2021;92(2):165-173. doi:10.5603/GP.2021.0043
  24. Monaghan TF, Rahman SN, Agudelo CW, et al. Foundational Statistical Principles in Medical Research: Sensitivity, Specificity, Positive Predictive Value, and Negative Predictive Value. Medicina (Kaunas) . 2021;57(5):503. Published 2021 May 16. doi:10.3390/medicina57050503
  25. Trevethan R. Sensitivity, Specificity, and Predictive Values: Foundations, Pliabilities, and Pitfalls in Research and Practice. Front Public Health . 2017;5:307. Published 2017 Nov 20. doi:10.3389/fpubh.2017.00307
  26. Trzeszcz M, Mazurec M, Jach R, et al. p16/Ki67 dual stain triage versus cytology in primary human papillomavirus-based cervical cancer screening with limited genotyping. J Med Virol . 2023;95(11):e29271. doi:10.1002/jmv.29271
  27. Mazurec K, Trzeszcz M, Mazurec M, Streb J, Halon A, Jach R. Triage Strategies for Non-16/Non-18 HPV-Positive Women in Primary HPV-Based Cervical Cancer Screening: p16/Ki67 Dual Stain vs. Cytology. Cancers (Basel) . 2023;15(20):5095. Published 2023 Oct 21. doi:10.3390/cancers15205095
  28. Trzeszcz M, Mazurec M, Jach R, et al. Is Primary HPV with Secondary p16/Ki67 Dual-Stain an Alternative HSIL-Risk Detection Strategy in Cervical Cancer Screening for Women under 30 Years?. Diagnostics (Basel) . 2021;11(11):2012. Published 2021 Oct 29. doi:10.3390/diagnostics11112012
  29. Trzeszcz M, Mazurec M, Jach R, et al. Liquid-Based Screening Tests Results: HPV, Liquid-Based Cytology, and P16/Ki67 Dual-Staining in Private-Based Opportunistic Cervical Cancer Screening. Diagnostics (Basel) . 2021;11(8):1420. Published 2021 Aug 5. doi:10.3390/diagnostics11081420
  30. Loghavi S, Walts AE, Bose S. CINtec® PLUS dual immunostain: a triage tool for cervical pap smears with atypical squamous cells of undetermined significance and low grade squamous intraepithelial lesion. Diagn Cytopathol . 2013;41(7):582-587. doi:10.1002/dc.22900
  31. National Cervical Cancer Screening Programme in Poland Coordinating Centre; Polish Gynaecological Society; Polish Society of Pathologists; Polish Society of Colposcopy and Uterine Cervix Pathology. Management of abnormal pap smear–consensus guidelines of the National Cervical Cancer Screening Programme in Poland Coordinating Centre, the Polish Gynaecological Society, the Polish Society of Pathologists, and Polish Society of Colposcopy and Uterine Cervix Pathology. Ginekol Pol . 2009;80(2):129-138.
  32. Krajowa Izba Diagnostów Laboratoryjnych; Polskie Towarzystwo Ginekologiczne. Wytyczne dotyczace aplikacji testów molekularnych identyfikujacych DNA HPV HR w profilaktyce szyjki macicy. Stanowisko ekspertów PTG i KIDL [Guidelines for application of molecular tests identyfying HR HPV DNA in the prevention of cervical cancer. Statement of experts from PGS (PTG) and NCLD (KIDL)]. Ginekol Pol . 2013;84(5):395-399.
  33. Massad LS, Einstein MH, Huh WK, et al. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Obstet Gynecol . 2013;121(4):829-846. doi:10.1097/AOG.0b013e3182883a34
  34. Huh WK, Ault KA, Chelmow D, et al. Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance. Obstet Gynecol . 2015;125(2):330-337. doi:10.1097/AOG.0000000000000669
  35. Darragh TM, Colgan TJ, Thomas Cox J, et al. The Lower Anogenital Squamous Terminology Standardization project for HPV-associated lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology [published correction appears in Int J Gynecol Pathol. 2013 Jul;32(4):432] [published correction appears in Int J Gynecol Pathol. 2013 Mar;32(2):241]. Int J Gynecol Pathol . 2013;32(1):76-115. doi:10.1097/PGP.0b013e31826916c7
  36. Kurman RJ, Carcangiu ML, Herrington CS. WHO Classification of Tumours of Female Reproductive Organs , 4th ed.; International Agency for Research on Cancer (IARC): Lyon, France, 2014.
  37. Leisenring W, Alonzo T, Pepe MS. Comparisons of predictive values of binary medical diagnostic tests for paired designs. Biometrics . 2000;56(2):345-351. doi:10.1111/j.0006-341x.2000.00345.x
  38. Hamers FF, Poullié AI, Arbyn M. Updated evidence-based recommendations for cervical cancer screening in France. Eur J Cancer Prev . 2022;31(3):279-286. doi:10.1097/CEJ.0000000000000701
  39. Wright TC Jr, Stoler MH, Ranger-Moore J, et al. Clinical validation of p16/Ki-67 dual-stained cytology triage of HPV-positive women: Results from the IMPACT trial. Int J Cancer . 2022;150(3):461-471. doi:10.1002/ijc.33812
  40. Øvestad IT, Dalen I, Andersland MS, et al. Triaging HPV-Positive Cervical Samples with p16 and Ki-67 Dual Stained Cytology within an Organized Screening Program-A Prospective Observational Study from Western Norway. Int J Mol Sci . 2023;24(8):7158. Published 2023 Apr 12. doi:10.3390/ijms24087158
  41. Naucler P, Ryd W, Törnberg S, et al. Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. J Natl Cancer Inst . 2009;101(2):88-99. doi:10.1093/jnci/djn444
  42. El-Zein M, Bouten S, Louvanto K, et al. Predictive Value of HPV Testing in Self-collected and Clinician-Collected Samples Compared with Cytology in Detecting High-grade Cervical Lesions. Cancer Epidemiol Biomarkers Prev . 2019;28(7):1134-1140. doi:10.1158/1055-9965.EPI-18-1338
  43. McGee AE, Alibegashvili T, Elfgren K, et al. European consensus statement on expert colposcopy. Eur J Obstet Gynecol Reprod Biol . 2023;290:27-37. doi:10.1016/j.ejogrb.2023.08.369